Details of the Drug Reposition

General Information of This Drug (ID: DMS90CU)

Drug Name
SGN-CD19A   DMS90CU
Synonyms Denintuzumab mafodotin
Structure
3D MOL is unavailable 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Diffuse large B-cell lymphoma DISSACK3 2A81 Phase 2 [1]
------------------------------------------------------------------------------------
2 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Acute lymphoblastic leukaemia DIS87TGM 2A85 Phase 1 [2]
Non-hodgkin lymphoma DISS2Y8A 2B33.5 Phase 1 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02855359) Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT01786135) A Safety Study of SGN-CD19A for B-Cell Lymphoma. U.S. National Institutes of Health.